Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
biotech
boston
boston blog main
2
×
boston top stories
2
×
life sciences
national blog main
national top stories
brexanalone
cancer
cancer immunotherapy
center for medicare and medicaid services
clinical data
companion diagnostic
daniel o'day
deals
depression
fda
foundation medicine
foundationone cdx
foundationone heme
genentech
jeff jonas
major depressive disorder
mental illness
neuroscience
new york blog main
osimertinib
phase 3 trial
postpartum depression
psychiatric disorders
roche
rucaparib (rubraca)
sage therapeutics
san francisco blog main
What
stock
2
×
acquire
agreed
approval
big
billion
brexanalone
broad
confidence
depression
didn’t
drug
fda
foundation
gain
genentech
hits
hour
infusion
mark
medical
medicine
momentum
morning
panels
pay
pays
phase
picked
postpartum
ppd
profiling
recently
redux
remaining
rest
roche
sage
share
soon
Language
Current search:
stock
×
photo
×
" boston blog main "
×
" boston top stories "
×
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine